How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved immune checkpoint inhibitors?

Emanuele CrocettiAlessandra RavaioliFabio FalciniRosa VattiatoSilvia ManciniFlavia BaldacchiniFederica ZamagniBenedetta VitaliChiara BalducciLauro BucchiOrietta Giuliani

Published in: Tumori (2024)

In conclusion, although the number of ICI-eligible patients is a relatively small proportion of the yearly burden of cancers, about half of them may respond to ICI-treatment.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
drug administration
patient reported outcomes
risk factors
patient reported
replacement therapy